Pneumagen
Saint Andrews
About Pneumagen
Pneumagen focuses on developing glycan targeted carbohydrate-binding modules (CBMs) as a new universal therapeutic modality for the treatment of respiratory tract infections (RTIs) and cancer. Founded in 2016, the Company is a spin-out from the University of St Andrews in Scotland and has access to world-class scientific expertise and capabilities in glycobiology.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $23.5M
- Last round: Series Unknown (Jun 2023)
- Website: pneumagen.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Wellness
Social Profiles
Canonical: https://fsome.com/organization/pneumagen-67363 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.